I'm not sure you are right about ATIII not posing a threat to coagulation in the absence of Heparin. I might be wrong but my understanding is ATII by itself blocks the coagulation cascade at several levels. Certainly in the JAMA article they mention the risk of hemorhagic complications from ATIII. The combination of anticoagulant and anti inflamatory actions of ATIII raises some exciting possibilities. I am most intrigued by the potential (as yet not studied) for Atryn to limit cellular apoptosis after CVAs or AMIs. Recently I had a chance to raise these questions with an acquaintence working on neurological diseases. He said he would look into it (he was not familiar with ATIII). He has not got back to me yet.
Market Data 
Markets 
AI
